Revlimid vs Keytruda
Side-by-side drug price comparison from Medicare Part D data
Verdict
Revlimid costs 30% less per claim than Keytruda ($12786.00 vs $18176.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Keytruda at $7.2B.
| Metric | Revlimid | Keytruda |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786* | $18,176 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $7.2B |
| Total Claims | 612,000 | 398,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4%* | 28.6% |
| Generic Available | No | No |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 58,000 | 82,000 |
Revlimid costs 30% less per claim than Keytruda ($12786.00 vs $18176.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Keytruda at $7.2B.